The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.50
Bid: 32.00
Ask: 33.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.125%)
Open: 32.50
High: 32.50
Low: 32.00
Prev. Close: 32.50
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update re: COVID-19

2 Apr 2020 07:00

RNS Number : 4967I
Duke Royalty Limited
02 April 2020
 

2 April 2020

 

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

 

Trading Update re: COVID-19

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, provides the following update regarding its response to the COVID-19 ("Covid") outbreak. 

 

Current Trading and Covid Update

 

For the financial year ending 31 March 2020 ("FY20"), the Company is pleased to report that cash revenue received from its royalty partners was in line with market expectations at over £10.0 million, with March 2020 contributing the greatest monthly cash revenue received by the Company to date at over £1.0 million. 

 

The health and wellbeing of our employees and stakeholders is the priority for the Company at this time. In response to the initial outbreak of Covid, Duke formulated and implemented its business continuity plan prior to the UK government's official request for employees to work from home where possible. From an operational standpoint, the continuity plan is proving effective and the Company is well placed to undertake its activities while its employees work remotely.

 

During March 2020, as the impact of the spread of Covid became prevalent across Duke's target geographical and market sectors, management has been focused on assessing the potential impact of Covid on its royalty partners' operations. The ongoing global response to Covid is evolving rapidly and management is in direct and continual contact with each of its royalty partners to assess their business outlook.

 

As we enter our financial year ending 31 March 2021 ("FY21"), the rapidly evolving Covid outbreak and the government's response to it has created an uncertain economic outlook. We know that some of our royalty partners have had, or will have, business interruption. While Duke has been able to build a diversified portfolio of royalty partners across geographies and industries, this will no doubt lead to a reduction in its royalty payments in the coming months. This in turn will have a negative impact on the fair value of the portfolio assets, leading to potential write downs in the FY20 year-end financials.

 

Duke would like to re-emphasise to its investors that it continues to be a high margin and profitable business with a low fixed cost base and is therefore well-placed to trade through this challenging period. The Company has strengthened its position further in light of the outbreak by implementing a number of cost-saving measures, including the deferral of all deployments into new royalty partners and reducing all non-core operational costs. These measures are not expected to materially compromise the Company's business prospects in the medium to long term and are expected to reduce the FY21 operating budget by over 25%, reflecting a material saving on FY20.

 

Outlook and liquidity

 

At this stage, it is too early to accurately assess the medium and longer-term impact of Covid across the Duke portfolio as a whole. Therefore, the Company wishes to withdraw its market guidance at this time, pending further clarity on the outlook. Every royalty partner has enacted cost-reduction plans and they are assessing what government relief funding may be available to assist them in trading during the Covid outbreak.

 

Duke retains its confidence in the quality and long-term prospects of the portfolio as a whole. If necessary to preserve long-term value, Duke will be willing to assist cash flow by deferring payments and/or providing additional financial support to its royalty partners on a case-by-case basis. Duke will continue to monitor the impact of Covid on its royalty partners and the associated level of cash royalty payments it will receive, and will keep the market updated accordingly. 

 

Duke is conservatively geared; after paying its dividend announced 11 March 2020, it will have net debt of approximately £13 million and a cash balance of £2.7 million. Based on Duke's internal 30% maximum loan to value limit, Duke currently has access to additional liquidity of approximately £18 million. It should also be noted that the recent drop in UK interest rates has lowered the cost of Duke's funding and that all the Company's debt is long term in nature with no amortisation payments due until September 2022. The Company remains compliant with its debt covenants.

 

Dividend

 

Duke recently confirmed its final quarterly dividend for Q4 FY20 at 0.75p, taking the full year pay-out to 2.95p per share. To date Duke has paid out over £12.7 million in dividends to shareholders and intends to continue to pay out a share of its operating cashflow to shareholders in future periods. In line with its regular reporting cycle, the Company's next quarterly dividend is scheduled to be announced in mid-June, by which time the Board hopes there will be better visibility on the long-term effects of Covid.

 

The situation in relation to Covid continues to evolve. However, Duke and its royalty partners are in a strong position to manage through this period of turbulence and the Board will keep shareholders updated as appropriate.

 

***ENDS***

 

For further information, please contact www.dukeroyalty.com, or contact:

 

Duke Royalty Limited

Neil Johnson / Charlie Cannon Brookes / Hugo Evans

 

+44 (0) 1481 741 240

Cenkos Securities plc 

(Nominated Adviser and Broker)

 

Stephen Keys / Callum Davidson / Julian Morse / Michael Johnson

 

+44 (0) 207 397 8900

Newgate Communications (PR)

Elisabeth Cowell/ Ian Silvera/ Megan Kovach

+ +44 (0) 20 3757 6880 dukeroyalty@newgatecomms.com

 

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFZGGDRMGGGZM
Date   Source Headline
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.